





Docket No. 2026-4269

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1643

Examiner: To Be Assigned

Filed For

Serial No

Novel Human Cancer Antigen NY ESO-1/CAG-3 and Gene Encoding Same

## CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

COMMISSIONER FOR PATENTS Washington, D.C. 20231

Sir:

WANG et al.

09/529,206

June 13, 2000

I hereby certify that the attached Information Disclosure Statement; Form PTO-1449 with 16

references; and Return postcard

along with any paper(s) referred to as being attached or enclosed) and this Certificate of Mailing are being deposited with the United States Postal Service on date shown below with sufficient postage as first-class mail in an envelope addressed to the: Commissioner for Patents, Washington, D.C. 20231.


Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: August 1, 2000

**CORRESPONDENCE ADDRESS: MORGAN & FINNEGAN LLP** 4345 Park Avenue New York, New York 10154 (212) 758-4800 (212) 751-6849 Facsimile

FORM: CERT..NY Rev. 05/27/98





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

WANG et al.

Serial No

09/529,206

Group Art Unit: 1643

Filed

June 13, 2000

Examiner: To Be Assigned

For

Novel Human Cancer Antigen NY ESO-1/CAG-3 and Gene Encoding Same

#### INFORMATION DISCLOSURE STATEMENT

COMMISSIONER FOR PATENTS Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1.	[]	For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:		
•				
J				
2.	[]	For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.		
3.	[]	Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Officin application Serial No, filed		
4.		No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being d in compliance with:		

		ij	filing date of the continued prosecution application filed on; or			
		[ ]	37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or			
		[X]	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office Action on the merits, whichever event occurred last.			
5.	[]	] No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.				
6.	[]	complia	due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in the with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing a final action or a notice of allowance (where there has been no prior final action):			
		[]	A check in the amount of \$240.00 is enclosed in payment of the fee.			
		[]	Charge the fee to Deposit Account No. 13-4500. Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.			
7.	due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in ance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, wer comes first, but before payment of the issue fee, and is accompanied by:					
		a. [ ]	one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and			
		b. [ ]	the attached petition requesting consideration of this Information Disclosure Statement; and			
		c. [ ]	the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in paragraph 10 below.			
8. [ ] A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure compliance with:			due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in ance with:			
•		a. []	37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;			
		b. [ ]	37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanies by the attached Petition To withdraw Application From Issue.			
		c. [ ]	The fee due under 37 C.F.R. §1.17(i)(1) is paid as set forth in paragraph 10 below.			
9.	[]	in a con	recrtify that each item of information contained in the Information Disclosure Statement was cited inmunication from a foreign patent office in a counterpart foreign application not more than three prior to the filing of this Information Disclosure Statement.			

Docket No. <u>2026-4269US1</u>

	[]	I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after make reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
10. [ ]	A check	in the amount of \$130.00 is enclosed in payn	nent of the fee due under C.F.R. §1.17(i)(1).			
	[]	Charge the fee due under C.F.R. §1.17(i)(1)  . A DUPLICATE CO	to Deposit Account No. 13-4500. Order No. PPY OF THIS SHEET IS ATTACHED.			
	[]	required for this Information Disclosure Stat	erized to charge any additional fees which may be ement, or credit any overpayment to Deposit Account . A DUPLICATE COPY OF THIS SHEET IS			
			Respectfully submitted,			
			MORGAN & FINNEGAN, L.L.P.			
Dated:	<u>August</u>	1, 2000	By: Haiyan Chen Registration No. 43,539			

#### CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P 345 Park Avenue New York, New York 10154 (212) 758-4800 (212) 751-6849 Facsimile

FORM: IDS.NY Rev. 05/26/98